Katherine S. Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Katherine S. Yang has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Ralph Weissleder
Massachusetts General Hospital
9 shared publications - Jonathan C. T. Carlson
Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, USA
4 shared publications - Hannah M. Peterson
Center for Systems Biology Massachusetts General Hospital Harvard Medial School 185 Cambridge Street, CPZN 5206 02114 Boston MA USA
3 shared publications - Joshua D. Spitzberg
Center for Systems Biology Massachusetts General Hospital Harvard Medial School 185 Cambridge Street, CPZN 5206 02114 Boston MA USA
3 shared publications - Scott Ferguson
Center for Systems Biology, Massachusetts General Hospital, 185 Cambridge St, CPZN 5206, Boston, MA 02114
3 shared publications - Andrew Scott Liss
Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, USA
2 shared publications
Latest Publications
- Open Access
- 24 September 2024
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 26 (12) , 1109-1128
Colocalization of Cancer-Associated Biomarkers on Single Extracellular Vesicles for Early Detection of Cancer
- 24 September 2024
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 26 (12) , 1109-1128
Open AccessColocalization of Cancer-Associated Biomarkers on Single Extracellular Vesicles for Early Detection of Cancer
- Open Access
- 3 May 2024
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 63 (24) , e202318870
Magnetic Silica‐Coated Fluorescent Microspheres (MagSiGlow) for Simultaneous Detection of Tumor‐Associated Proteins
Multiplexed bead assays for solution‐phase biosensing often encounter cross‐over reactions during signal amplification steps, leading to unwanted false positive and high background signals. Current solutions involve complex custom‐designed and costly equipment, limiting their application in simple laboratory setup. In this study, we introduce a straightforward protocol to adapt a multiplexed single‐bead assay to standard fluorescence imaging plates, enabling the simultaneous analysis of thousands of reactions per plate. This approach focuses on the design and synthesis of bright fluorescent and magnetic microspheres (MagSiGlow) with multiple fluorescent wavelengths serving as unique detection markers. The imaging‐based, single‐bead assay, combined with a scripted algorithm, allows the detection, segmentation, and co‐localization on average of 7500 microspheres per field of view across five imaging channels in less than one second. We demonstrate the effectiveness of this method with remarkable sensitivity at low protein detection limits (100 pg/mL). This technique showed over 85 % reduction in signal cross‐over to the solution‐based method after the concurrent detection of tumor‐associated protein biomarkers. This approach holds the promise of substantially enhancing high throughput biosensing for multiple targets, seamlessly integrating with rapid image analysis algorithms.
- 3 May 2024
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 63 (24) , e202318870
Open AccessMagnetic Silica‐Coated Fluorescent Microspheres (MagSiGlow) for Simultaneous Detection of Tumor‐Associated Proteins
Multiplexed bead assays for solution‐phase biosensing often encounter cross‐over reactions during signal amplification steps, leading to unwanted false positive and high background signals. Current solutions involve complex custom‐designed and costly equipment, limiting their application in simple laboratory setup. In this study, we introduce a straightforward protocol to adapt a multiplexed single‐bead assay to standard fluorescence imaging plates, enabling the simultaneous analysis of thousands of reactions per plate. This approach focuses on the design and synthesis of bright fluorescent and magnetic microspheres (MagSiGlow) with multiple fluorescent wavelengths serving as unique detection markers. The imaging‐based, single‐bead assay, combined with a scripted algorithm, allows the detection, segmentation, and co‐localization on average of 7500 microspheres per field of view across five imaging channels in less than one second. We demonstrate the effectiveness of this method with remarkable sensitivity at low protein detection limits (100 pg/mL). This technique showed over 85 % reduction in signal cross‐over to the solution‐based method after the concurrent detection of tumor‐associated protein biomarkers. This approach holds the promise of substantially enhancing high throughput biosensing for multiple targets, seamlessly integrating with rapid image analysis algorithms.
- Open Access
- 3 May 2024
- Published by Wiley in Angewandte Chemie
- Vol. 136 (24) , e202318870
Magnetic Silica‐Coated Fluorescent Microspheres (MagSiGlow) for Simultaneous Detection of Tumor‐Associated Proteins
Multiplexed bead assays for solution‐phase biosensing often encounter cross‐over reactions during signal amplification steps, leading to unwanted false positive and high background signals. Current solutions involve complex custom‐designed and costly equipment, limiting their application in simple laboratory setup. In this study, we introduce a straightforward protocol to adapt a multiplexed single‐bead assay to standard fluorescence imaging plates, enabling the simultaneous analysis of thousands of reactions per plate. This approach focuses on the design and synthesis of bright fluorescent and magnetic microspheres (MagSiGlow) with multiple fluorescent wavelengths serving as unique detection markers. The imaging‐based, single‐bead assay, combined with a scripted algorithm, allows the detection, segmentation, and co‐localization on average of 7500 microspheres per field of view across five imaging channels in less than one second. We demonstrate the effectiveness of this method with remarkable sensitivity at low protein detection limits (100 pg/mL). This technique showed over 85 % reduction in signal cross‐over to the solution‐based method after the concurrent detection of tumor‐associated protein biomarkers. This approach holds the promise of substantially enhancing high throughput biosensing for multiple targets, seamlessly integrating with rapid image analysis algorithms.
- 3 May 2024
- Published by Wiley in Angewandte Chemie
- Vol. 136 (24) , e202318870
Open AccessMagnetic Silica‐Coated Fluorescent Microspheres (MagSiGlow) for Simultaneous Detection of Tumor‐Associated Proteins
Multiplexed bead assays for solution‐phase biosensing often encounter cross‐over reactions during signal amplification steps, leading to unwanted false positive and high background signals. Current solutions involve complex custom‐designed and costly equipment, limiting their application in simple laboratory setup. In this study, we introduce a straightforward protocol to adapt a multiplexed single‐bead assay to standard fluorescence imaging plates, enabling the simultaneous analysis of thousands of reactions per plate. This approach focuses on the design and synthesis of bright fluorescent and magnetic microspheres (MagSiGlow) with multiple fluorescent wavelengths serving as unique detection markers. The imaging‐based, single‐bead assay, combined with a scripted algorithm, allows the detection, segmentation, and co‐localization on average of 7500 microspheres per field of view across five imaging channels in less than one second. We demonstrate the effectiveness of this method with remarkable sensitivity at low protein detection limits (100 pg/mL). This technique showed over 85 % reduction in signal cross‐over to the solution‐based method after the concurrent detection of tumor‐associated protein biomarkers. This approach holds the promise of substantially enhancing high throughput biosensing for multiple targets, seamlessly integrating with rapid image analysis algorithms.
- Top Cited PapersOpen Access
- 4 March 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-12
Multiplexed analysis of EV reveals specific biomarker composition with diagnostic impact
Exosomes and extracellular vesicles (EV) are increasingly being explored as circulating biomarkers, but their heterogenous composition will likely mandate the development of multiplexed EV technologies. Iteratively multiplexed analyses of near single EVs have been challenging to implement beyond a few colors during spectral sensing. Here we developed a multiplexed analysis of EV technique (MASEV) to interrogate thousands of individual EVs during 5 cycles of multi-channel fluorescence staining for 15 EV biomarkers. Contrary to the common belief, we show that: several markers proposed to be ubiquitous are less prevalent than believed; multiple biomarkers concur in single vesicles but only in small fractions; affinity purification can lead to loss of rare EV subtypes; and deep profiling allows detailed analysis of EV, potentially improving the diagnostic content. These findings establish the potential of MASEV for uncovering fundamental EV biology and heterogeneity and increasing diagnostic specificity.
- 4 March 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-12
Top Cited PapersOpen AccessMultiplexed analysis of EV reveals specific biomarker composition with diagnostic impact
Exosomes and extracellular vesicles (EV) are increasingly being explored as circulating biomarkers, but their heterogenous composition will likely mandate the development of multiplexed EV technologies. Iteratively multiplexed analyses of near single EVs have been challenging to implement beyond a few colors during spectral sensing. Here we developed a multiplexed analysis of EV technique (MASEV) to interrogate thousands of individual EVs during 5 cycles of multi-channel fluorescence staining for 15 EV biomarkers. Contrary to the common belief, we show that: several markers proposed to be ubiquitous are less prevalent than believed; multiple biomarkers concur in single vesicles but only in small fractions; affinity purification can lead to loss of rare EV subtypes; and deep profiling allows detailed analysis of EV, potentially improving the diagnostic content. These findings establish the potential of MASEV for uncovering fundamental EV biology and heterogeneity and increasing diagnostic specificity.
- 24 May 2022
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 28 (8) , 681-692
Single extracellular vesicle analysis for early cancer detection
- 24 May 2022
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 28 (8) , 681-692
Single extracellular vesicle analysis for early cancer detection
- Open Access
- 22 April 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (16) , eabm3453
Single-EV analysis (sEVA) of mutated proteins allows detection of stage 1 pancreatic cancer
Tumor cell–derived extracellular vesicles (EVs) are being explored as circulating biomarkers, but it is unclear whether bulk measurements will allow early cancer detection. We hypothesized that a single-EV analysis (sEVA) technique could potentially improve diagnostic accuracy. Using pancreatic cancer (PDAC), we analyzed the composition of putative cancer markers in 11 model lines. In parental PDAC cells positive for KRAS mut and/or P53 mut proteins, only ~40% of EVs were also positive. In a blinded study involving 16 patients with surgically proven stage 1 PDAC, KRAS mut and P53 mut protein was detectable at much lower levels, generally in 3 tumor volume, below clinical imaging capabilities. These findings establish the potential for sEVA for early cancer detection.
- 22 April 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (16) , eabm3453
Open AccessSingle-EV analysis (sEVA) of mutated proteins allows detection of stage 1 pancreatic cancer
Tumor cell–derived extracellular vesicles (EVs) are being explored as circulating biomarkers, but it is unclear whether bulk measurements will allow early cancer detection. We hypothesized that a single-EV analysis (sEVA) technique could potentially improve diagnostic accuracy. Using pancreatic cancer (PDAC), we analyzed the composition of putative cancer markers in 11 model lines. In parental PDAC cells positive for KRAS mut and/or P53 mut proteins, only ~40% of EVs were also positive. In a blinded study involving 16 patients with surgically proven stage 1 PDAC, KRAS mut and P53 mut protein was detectable at much lower levels, generally in 3 tumor volume, below clinical imaging capabilities. These findings establish the potential for sEVA for early cancer detection.
- Open Access
Single EV analysis (sEVA) of mutated proteins allows detection of stage 1 pancreatic cancer
Tumor cell derived extracellular vesicles (EV) are being explored as circulating biomarkers for cancer detection. Up to now however, clinical results have been mixed for a number of reasons including the predominant use of bulk measurements, the inability to differentiate tumor from host cell derived vesicles, the general absence of uniquely identifying biomarkers and the unknown frequency of stochastically distributed biomarkers into single circulating vesicles. We hypothesized that a single EV analysis (sEVA) technique could potentially improve diagnostic accuracy necessary to detect early cancers but the actual biomarker frequency and practical detection limits are currently unknown. Using pancreatic cancer, we carefully analyzed the composition of putative cancer markers in 11 established and new patient derived models. In parental PDAC cells positive for KRAS mut and/or P53 mut proteins only ∼40% of EVs were also positive (range: 30-64%). This rate of positivity increased to 57% when additional PDAC biomarkers were considered (MUC1, EGFR, ⍺FG-P4OH) in cell lines. In a blinded study involving 16 patients with surgically proven stage 1 PDAC, KRAS mut and P53 mut protein was detectable at much lower levels, generally in < 0.1% of vesicles. With the analytical capabilities of sEVA however, 15 of the 16 patients with stage 1 PDAC expressed low levels of biomarker positive EV. Using a modeling approach, we estimate that the current PDAC detection limit is at ∼0.1 cm 3 tumor volume, below clinical imaging capabilities. These findings establish the potential for single-EV analysis for early cancer detection.
Open AccessSingle EV analysis (sEVA) of mutated proteins allows detection of stage 1 pancreatic cancer
Tumor cell derived extracellular vesicles (EV) are being explored as circulating biomarkers for cancer detection. Up to now however, clinical results have been mixed for a number of reasons including the predominant use of bulk measurements, the inability to differentiate tumor from host cell derived vesicles, the general absence of uniquely identifying biomarkers and the unknown frequency of stochastically distributed biomarkers into single circulating vesicles. We hypothesized that a single EV analysis (sEVA) technique could potentially improve diagnostic accuracy necessary to detect early cancers but the actual biomarker frequency and practical detection limits are currently unknown. Using pancreatic cancer, we carefully analyzed the composition of putative cancer markers in 11 established and new patient derived models. In parental PDAC cells positive for KRAS mut and/or P53 mut proteins only ∼40% of EVs were also positive (range: 30-64%). This rate of positivity increased to 57% when additional PDAC biomarkers were considered (MUC1, EGFR, ⍺FG-P4OH) in cell lines. In a blinded study involving 16 patients with surgically proven stage 1 PDAC, KRAS mut and P53 mut protein was detectable at much lower levels, generally in < 0.1% of vesicles. With the analytical capabilities of sEVA however, 15 of the 16 patients with stage 1 PDAC expressed low levels of biomarker positive EV. Using a modeling approach, we estimate that the current PDAC detection limit is at ∼0.1 cm 3 tumor volume, below clinical imaging capabilities. These findings establish the potential for single-EV analysis for early cancer detection.
- Top Cited PapersOpen Access
- 2 March 2018
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 4 (3) , eaar2766
Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles
Binding of programmed death ligand-1 (PD-L1) to programmed cell death protein-1 (PD1) leads to cancer immune evasion via inhibition of T cell function. One of the defining characteristics of glioblastoma, a universally fatal brain cancer, is its profound local and systemic immunosuppression. Glioblastoma has also been shown to generate extracellular vesicles (EVs), which may play an important role in tumor progression. We thus hypothesized that glioblastoma EVs may be important mediators of immunosuppression and that PD-L1 could play a role. We show that glioblastoma EVs block T cell activation and proliferation in response to T cell receptor stimulation. PD-L1 was expressed on the surface of some, but not of all, glioblastoma-derived EVs, with the potential to directly bind to PD1. An anti-PD1 receptor blocking antibody significantly reversed the EV-mediated blockade of T cell activation but only when PD-L1 was present on EVs. When glioblastoma PD-L1 was up-regulated by IFN-γ, EVs also showed some PD-L1–dependent inhibition of T cell activation. PD-L1 expression correlated with the mesenchymal transcriptome profile and was anatomically localized in the perinecrotic and pseudopalisading niche of human glioblastoma specimens. PD-L1 DNA was present in circulating EVs from glioblastoma patients where it correlated with tumor volumes of up to 60 cm3. These results suggest that PD-L1 on EVs may be another mechanism for glioblastoma to suppress antitumor immunity and support the potential of EVs as biomarkers in tumor patients.
- 2 March 2018
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 4 (3) , eaar2766
Top Cited PapersOpen AccessImmune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles
Binding of programmed death ligand-1 (PD-L1) to programmed cell death protein-1 (PD1) leads to cancer immune evasion via inhibition of T cell function. One of the defining characteristics of glioblastoma, a universally fatal brain cancer, is its profound local and systemic immunosuppression. Glioblastoma has also been shown to generate extracellular vesicles (EVs), which may play an important role in tumor progression. We thus hypothesized that glioblastoma EVs may be important mediators of immunosuppression and that PD-L1 could play a role. We show that glioblastoma EVs block T cell activation and proliferation in response to T cell receptor stimulation. PD-L1 was expressed on the surface of some, but not of all, glioblastoma-derived EVs, with the potential to directly bind to PD1. An anti-PD1 receptor blocking antibody significantly reversed the EV-mediated blockade of T cell activation but only when PD-L1 was present on EVs. When glioblastoma PD-L1 was up-regulated by IFN-γ, EVs also showed some PD-L1–dependent inhibition of T cell activation. PD-L1 expression correlated with the mesenchymal transcriptome profile and was anatomically localized in the perinecrotic and pseudopalisading niche of human glioblastoma specimens. PD-L1 DNA was present in circulating EVs from glioblastoma patients where it correlated with tumor volumes of up to 60 cm3. These results suggest that PD-L1 on EVs may be another mechanism for glioblastoma to suppress antitumor immunity and support the potential of EVs as biomarkers in tumor patients.
- Top Cited Papers
- 24 May 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 9 (391)
Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy
Pancreatic ductal adenocarcinoma (PDAC) is usually detected late in the disease process. Clinical workup through imaging and tissue biopsies is often complex and expensive due to a paucity of reliable biomarkers. We used an advanced multiplexed plasmonic assay to analyze circulating tumor-derived extracellular vesicles (tEVs) in more than 100 clinical populations. Using EV-based protein marker profiling, we identified a signature of five markers (PDACEV signature) for PDAC detection. In our prospective cohort, the accuracy for the PDACEV signature was 84% [95% confidence interval (CI), 69 to 93%] but only 63 to 72% for single-marker screening. One of the best markers, GPC1 alone, had a sensitivity of 82% (CI, 60 to 95%) and a specificity of 52% (CI, 30 to 74%), whereas the PDACEV signature showed a sensitivity of 86% (CI, 65 to 97%) and a specificity of 81% (CI, 58 to 95%). The PDACEV signature of tEVs offered higher sensitivity, specificity, and accuracy than the existing serum marker (CA 19-9) or single–tEV marker analyses. This approach should improve the diagnosis of pancreatic cancer.
- 24 May 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 9 (391)
Top Cited PapersMultiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy
Pancreatic ductal adenocarcinoma (PDAC) is usually detected late in the disease process. Clinical workup through imaging and tissue biopsies is often complex and expensive due to a paucity of reliable biomarkers. We used an advanced multiplexed plasmonic assay to analyze circulating tumor-derived extracellular vesicles (tEVs) in more than 100 clinical populations. Using EV-based protein marker profiling, we identified a signature of five markers (PDACEV signature) for PDAC detection. In our prospective cohort, the accuracy for the PDACEV signature was 84% [95% confidence interval (CI), 69 to 93%] but only 63 to 72% for single-marker screening. One of the best markers, GPC1 alone, had a sensitivity of 82% (CI, 60 to 95%) and a specificity of 52% (CI, 30 to 74%), whereas the PDACEV signature showed a sensitivity of 86% (CI, 65 to 97%) and a specificity of 81% (CI, 58 to 95%). The PDACEV signature of tEVs offered higher sensitivity, specificity, and accuracy than the existing serum marker (CA 19-9) or single–tEV marker analyses. This approach should improve the diagnosis of pancreatic cancer.
- Top Cited Papers
- 10 May 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 9 (389)
In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy
Tumor-associated macrophages limit anti–PD-1 effects by removing the antibody from CD8 + T cells.
- 10 May 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 9 (389)
Top Cited PapersIn vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy
Tumor-associated macrophages limit anti–PD-1 effects by removing the antibody from CD8 + T cells.